Gaurav Banka, MD
Internal Medicine · Torrance
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
- Since medical school
- 15 years
- Stanford University School of Medicine, 2011
Offices
4 locations · Torrance Memorial Medical Center · Cor Healthcare Medical Associates · Torrance Health Association Inc · Southern California Hospitalist Network Medical Group Inc
Hospitals listed: Providence Little Company of Mary Med Ctr Torrance · Torrance Memorial Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Banka’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A123190 · Current
Licensed to practise in California · since 2012 · expires 2026-10-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Cardiology
- American Board of Internal Medicine - Cardiovascular Disease
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Providence Little Company of Mary Med Ctr TorranceTorrance, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.472, Oct 2024 – Sep 2025
- Torrance Memorial Medical CenterTorrance, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Cedars Sinai Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 82% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.36 (1.11 to 1.61), Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 15.79 (10.51 to 21.07) · 1,494 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.21 (0.72 to 1.71) · 9,154 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.328, Oct 2024 – Sep 2025
See every measure and the patient survey for Providence Little Company of Mary Med Ctr Torrance
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 8 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.472 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.09 (0.11 to 2.07) · 1,022 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.59 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 129.31 (75.73 to 182.88) · 65 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 70 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.4 · 353 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 361 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 495 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 3,150 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 5,786 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.06 to 0.45) · 5,832 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.21 (2.1 to 6.32) · 1,135 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.81 (0.22 to 3.4) · 375 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.8 to 3.86) · 1,086 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.78 (2.28 to 15.28) · 389 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.58 (1.19 to 7.98) · 377 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2 (0.51 to 3.49) · 247 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 0.93) · 4,918 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.892 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.225 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.363 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 283 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 709 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 10.5 · 149 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.9 · 428 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -13.8 · 369 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 551 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 59 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 168 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (8.9 to 15.5) · 642 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 331 cases | No different | Jan 2024 – Dec 2024 |
What patients said (414 patients answered, 18% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for Torrance Memorial Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 1 worse of 8 measures. Readmissions: 0 better, 8 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.36 (1.11 to 1.61) | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 15.79 (10.51 to 21.07) · 1,494 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.21 (0.72 to 1.71) · 9,154 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.328 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.72) · 2,154 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 171.72 (128.91 to 214.54) · 121 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8 · 136 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 176 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.8 · 766 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 806 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 608 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 7,587 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.28 (0.1 to 0.47) · 11,109 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.03 to 0.39) · 11,330 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.13 (2.41 to 5.85) · 2,964 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0.13 to 3.16) · 1,513 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.66 (1.3 to 4.01) · 2,802 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.24 (2.35 to 8.14) · 1,479 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.55 (0.11 to 2.98) · 650 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2 · 962 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.023 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.646 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.751 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.259 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.658 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 1,578 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 21.1 · 183 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.5 · 900 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.9 · 800 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.1 · 1,223 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.3) · 26 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.5 (7 to 15) · 26 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 928 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12 · 65 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21 · 316 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.5 to 16.1) · 624 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 781 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,607 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 78% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 82% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$436,641
Medicare paid this office $436,641 for 2,313 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 156 | $76,847 | $41 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 231 | $74,765 | $43 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 187 | $74,250 | $51 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 210 | $35,203 | $41 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 140 | $25,392 | $33 |
See all 36 services
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 156 | $76,847 | $41 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 231 | $74,765 | $43 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 187 | $74,250 | $51 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 210 | $35,203 | $41 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 140 | $25,392 | $33 |
| Return visit (30+ min) | 258 | $25,380 | $75 |
| Long return visit (40+ min) | 139 | $19,680 | $113 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 261 | $14,412 | $54 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 1,513 | $11,571 | $6 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $11,519 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 139 | $10,905 | $77 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $8,493 | $142 |
| Critical care, first 30-74 minutes | 23 | $6,583 | $173 |
| New patient visit (60+ min) | 43 | $6,534 | $152 |
| New patient visit (45+ min) | 62 | $6,143 | $99 |
| Telephone medical discussion with physician, 21-30 minutes | 50 | $4,525 | $82 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 58 | $3,341 | $58 |
| Ultrasound of heart with probe in esophagus, with report | 38 | $3,144 | $79 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 126 | $2,028 | $14 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 210 | $1,331 | $6 |
| Return visit (30+ min) | 15 | $1,208 | $81 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 38 | $1,182 | $28 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 75 | $1,179 | $16 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 59 | $993 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 58 | $972 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 76 | $788 | $10 |
| Ultrasound of heart, follow-up | 29 | $651 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 58 | $640 | $11 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $614 | $41 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 27 | $510 | $18 |
| Ultrasound of heart blood flow, valves and chambers | 33 | $464 | $14 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 20 | $459 | $21 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 13 | $289 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 22 | $210 | $10 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 13 | $166 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 37 | $93 | $2 |
Who their Medicare patients are
2,313 Original Medicare patients in 2024. Average age 77 · Under 65 7% · 85 and older 25% · Women 54% · Also on Medicaid 28% · Health risk score 2.00. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Coronary heart disease 45% · Diabetes 44% · Chronic kidney disease 42% · Heart failure 39% · Atrial fibrillation 35% · Depression 26% · Cancer 20% · COPD 20% · Stroke 20% · Dementia 17%.
The office billed $1,277,067, Medicare allowed $570,123 and paid $436,641; for 10,968 services of 54 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 2,313 | 10,968 | 77 | 2.00 | $1,277,067 | $436,641 |
| 2023 | 1,351 | 8,455 | 77 | 1.97 | $1,076,981 | $375,380 |
| 2022 | 1,405 | 7,860 | 77 | 2.00 | $988,374 | $359,734 |
| 2021 | 1,353 | 4,946 | 77 | 2.11 | $585,022 | $210,580 |
| 2020 | 1,071 | 2,388 | 77 | 2.25 | $332,249 | $96,859 |
| 2019 | 1,234 | 2,721 | 77 | 2.24 | $370,985 | $104,716 |
| 2018 | 866 | 2,231 | 77 | 1.90 | $350,110 | $97,234 |
| 2017 | 205 | 325 | 77 | 1.77 | $59,356 | $17,450 |
| 2016 | 23 | 35 | 76 | 1.44 | $7,810 | $1,666 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 34 services
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 195 | $74,892 | $52 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 196 | $71,493 | $45 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 188 | $60,660 | $41 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 129 | $26,766 | $41 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 119 | $23,748 | $33 |
| Return visit (30+ min) | 212 | $19,046 | $75 |
| Long return visit (40+ min) | 108 | $18,364 | $112 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 198 | $10,703 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $8,773 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $7,677 | $137 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 109 | $7,464 | $66 |
| New patient visit (45+ min) | 67 | $6,666 | $99 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 87 | $5,334 | $61 |
| Critical care, first 30-74 minutes | 20 | $4,410 | $163 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 559 | $4,270 | $7 |
| New patient visit (60+ min) | 23 | $3,600 | $157 |
| Ultrasound of heart with probe in esophagus, with report | 35 | $3,208 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $2,188 | $66 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 98 | $1,646 | $17 |
| Telephone medical discussion with physician, 21-30 minutes | 19 | $1,384 | $73 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 98 | $1,098 | $11 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 157 | $959 | $6 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 50 | $857 | $17 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 17 | $539 | $30 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 29 | $447 | $14 |
| Ultrasound of heart blood flow, valves and chambers | 24 | $371 | $15 |
| Ultrasound of heart, follow-up | 17 | $332 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 16 | $284 | $18 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 20 | $266 | $12 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 12 | $256 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 16 | $187 | $12 |
| 3d radiographic procedure | 19 | $143 | $8 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 35 | $95 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $71 | $6 |
2022: 35 services
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 210 | $82,139 | $53 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 160 | $71,367 | $50 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 166 | $56,871 | $43 |
| Return visit (30+ min) | 238 | $23,002 | $78 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 103 | $17,793 | $35 |
| Long return visit (40+ min) | 88 | $15,087 | $124 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 180 | $10,613 | $59 |
| New patient visit (45+ min) | 86 | $9,666 | $112 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 114 | $9,241 | $78 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 95 | $8,225 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $6,578 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $6,430 | $157 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 99 | $6,000 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 651 | $5,299 | $7 |
| Critical care, first 30-74 minutes | 19 | $4,359 | $182 |
| New patient visit (60+ min) | 26 | $3,916 | $151 |
| Ultrasound of heart with probe in esophagus, with report | 33 | $3,126 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $1,985 | $57 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 105 | $1,766 | $17 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $1,450 | $81 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 105 | $1,205 | $11 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 178 | $1,185 | $6 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 69 | $1,180 | $17 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 11 | $783 | $71 |
| Ultrasound of heart, follow-up | 27 | $578 | $21 |
| Short return visit (20+ min) | 11 | $559 | $51 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 28 | $520 | $19 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 36 | $457 | $12 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 26 | $412 | $15 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 28 | $348 | $12 |
| Ultrasound of heart blood flow, valves and chambers | 19 | $306 | $15 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 13 | $298 | $23 |
| 3d radiographic procedure | 14 | $107 | $8 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 31 | $85 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $73 | $6 |
2021: 32 services
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 110 | $34,396 | $58 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 178 | $31,652 | $35 |
| Return visit (30+ min) | 222 | $23,254 | $76 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 106 | $23,089 | $45 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 128 | $9,979 | $75 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $7,946 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $7,687 | $88 |
| New patient visit (45+ min) | 71 | $7,557 | $106 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 124 | $7,390 | $59 |
| Long return visit (40+ min) | 45 | $7,161 | $121 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 101 | $6,654 | $66 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 716 | $5,828 | $7 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 50 | $4,797 | $36 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $3,922 | $60 |
| Ultrasound of heart with probe in esophagus, with report | 34 | $3,164 | $88 |
| Telephone medical discussion with physician, 21-30 minutes | 38 | $3,082 | $75 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 114 | $1,960 | $17 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,613 | $115 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 77 | $1,469 | $18 |
| Short return visit (20+ min) | 25 | $1,360 | $54 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 114 | $1,335 | $12 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 16 | $1,161 | $73 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 143 | $1,059 | $7 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 24 | $535 | $22 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 24 | $405 | $16 |
| Ultrasound of heart, follow-up | 14 | $327 | $22 |
| Ultrasound of heart blood flow, valves and chambers | 23 | $319 | $14 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 14 | $264 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 14 | $176 | $13 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 12 | $133 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 34 | $91 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 13 | $81 | $6 |
2020: 30 services
| Return visit (30+ min) | 152 | $12,444 | $60 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 118 | $7,083 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 59 | $6,771 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $6,619 | $165 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 121 | $6,613 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $5,617 | $89 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 93 | $5,514 | $59 |
| Ultrasound of heart with probe in esophagus, with report | 48 | $4,688 | $96 |
| Critical care, first 30-74 minutes | 22 | $4,586 | $176 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 29 | $4,513 | $59 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 502 | $4,037 | $7 |
| New patient visit (45+ min) | 40 | $3,908 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,167 | $109 |
| Telephone medical discussion with physician, 21-30 minutes | 40 | $3,023 | $69 |
| Long return visit (40+ min) | 25 | $2,412 | $86 |
| Short return visit (20+ min) | 56 | $2,180 | $36 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 101 | $1,743 | $17 |
| External shock to heart to regulate heart beat | 13 | $1,252 | $96 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 102 | $1,229 | $12 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 13 | $966 | $74 |
| Anticoagulant management of patient taking warfarin | 21 | $960 | $9 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 30 | $526 | $18 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 68 | $446 | $6 |
| Ultrasound of heart blood flow, valves and chambers | 24 | $385 | $16 |
| Ultrasound of heart, follow-up | 16 | $364 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 20 | $348 | $17 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 14 | $323 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 20 | $233 | $12 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 20 | $134 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 44 | $125 | $3 |
2019: 28 services
| Return visit (30+ min) | 124 | $10,618 | $62 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 171 | $10,561 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 85 | $9,720 | $61 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 149 | $9,386 | $62 |
| Ultrasound of heart with probe in esophagus, with report | 80 | $7,963 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 112 | $6,658 | $58 |
| Critical care, first 30-74 minutes | 25 | $6,257 | $184 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 54 | $5,913 | $108 |
| New patient visit (45+ min) | 58 | $5,796 | $100 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 579 | $4,751 | $7 |
| Short return visit (20+ min) | 72 | $3,202 | $37 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 176 | $3,132 | $18 |
| Long return visit (40+ min) | 24 | $2,961 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,203 | $88 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 176 | $2,112 | $12 |
| New patient visit (60+ min) | 11 | $1,568 | $143 |
| External shock to heart to regulate heart beat | 11 | $1,043 | $95 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 12 | $878 | $73 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 104 | $858 | $7 |
| Ultrasound of heart blood flow, valves and chambers | 46 | $740 | $16 |
| Return visit (30+ min) | 11 | $736 | $67 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 38 | $722 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 38 | $483 | $13 |
| Ultrasound of heart, follow-up | 17 | $441 | $21 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 16 | $350 | $22 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 16 | $328 | $20 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 72 | $202 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 27 | $170 | $6 |
2018: 24 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 224 | $14,049 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 115 | $13,412 | $60 |
| Return visit (30+ min) | 74 | $8,034 | $66 |
| Ultrasound of heart with probe in esophagus, with report | 76 | $7,559 | $90 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 125 | $7,495 | $59 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 115 | $7,072 | $61 |
| Short return visit (20+ min) | 97 | $6,683 | $38 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 58 | $6,525 | $109 |
| New patient visit (45+ min) | 53 | $5,030 | $95 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 235 | $4,239 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 235 | $2,865 | $12 |
| Critical care, first 30-74 minutes | 11 | $2,287 | $176 |
| New patient visit (30+ min) | 38 | $1,830 | $48 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 129 | $1,030 | $7 |
| Return visit (30+ min) | 17 | $1,003 | $59 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 35 | $665 | $19 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 99 | $654 | $6 |
| Ultrasound of heart blood flow, valves and chambers | 30 | $472 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 35 | $445 | $13 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 14 | $312 | $22 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 13 | $269 | $21 |
| Ultrasound of heart, follow-up | 11 | $264 | $22 |
| Anticoagulant management of patient taking warfarin | 11 | $210 | $9 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 31 | $84 | $3 |
2017: 10 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,672 | $116 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 39 | $2,378 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,176 | $59 |
| New patient visit (30+ min) | 31 | $2,013 | $65 |
| Ultrasound of heart with probe in esophagus, with report | 18 | $1,869 | $93 |
| New patient visit (45+ min) | 14 | $1,604 | $115 |
| Short return visit (20+ min) | 31 | $1,557 | $43 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 25 | $1,364 | $55 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 35 | $252 | $7 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 24 | $184 | $7 |
2016: 1 service
| Short return visit (20+ min) | 23 | $1,517 | $63 |
Medicaid work
$8,776 in 2024
Medicaid paid $8,776 for 1,010 billed services this clinician did in 2024, up to 121 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 953 | $6,770 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 57 | $2,006 |
| 2024 | 1,010 | 2 | 121 | $8,776 |
| 2023 | 566 | 3 | 96 | $6,298 |
| 2022 | 593 | 3 | 111 | $6,673 |
| 2021 | 487 | 1 | 93 | $4,105 |
| 2020 | 247 | 1 | 70 | $2,173 |
| 2019 | 291 | 1 | 71 | $2,540 |
| 2018 | 71 | 1 | 29 | $542 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 533 | $4,976 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 21 | $1,121 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 12 | $201 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 568 | $4,669 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 12 | $1,705 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 13 | $300 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 487 | $4,105 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 247 | $2,173 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 291 | $2,540 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 71 | $542 |
Drugs they prescribed that Part D paid
$1,334,468
Pharmacies billed $1,334,468 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 4,027) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
3,020 generic and fewer than 11 brand-name prescriptions · $1,334,468 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 411 | $517,870 | $1,260 |
| Entresto | 135 | $171,156 | $1,268 |
| Xarelto | 96 | $118,455 | $1,234 |
| Jardiance | 97 | $107,499 | $1,108 |
| Repatha Sureclick | 67 | $65,972 | $985 |
See all 41 drugs
| Eliquis | 411 | $517,870 | $1,260 |
| Entresto | 135 | $171,156 | $1,268 |
| Xarelto | 96 | $118,455 | $1,234 |
| Jardiance | 97 | $107,499 | $1,108 |
| Repatha Sureclick | 67 | $65,972 | $985 |
| Farxiga | 50 | $60,785 | $1,216 |
| Ozempic | 28 | $29,724 | $1,062 |
| Brilinta | 25 | $16,276 | $651 |
| Praluent | 14 | $13,681 | $977 |
| Ranolazine Er | 102 | $8,981 | $88 |
| Metoprolol | 340 | $5,780 | $17 |
| Atorvastatin | 420 | $4,934 | $12 |
| Rosuvastatin | 249 | $4,009 | $16 |
| Ezetimibe | 123 | $2,712 | $22 |
| Amlodipine Besylate | 260 | $2,017 | $8 |
| Hydralazine | 98 | $2,001 | $20 |
| Carvedilol | 169 | $1,444 | $9 |
| Clopidogrel | 119 | $1,372 | $12 |
| Losartan | 118 | $1,263 | $11 |
| Flecainide Acetate | 25 | $1,250 | $50 |
| Amiodarone | 26 | $1,188 | $46 |
| Diltiazem 24hr Er (Cd) | 34 | $1,161 | $34 |
| Potassium Chloride | 27 | $829 | $31 |
| Metoprolol | 111 | $682 | $6 |
| Spironolactone | 87 | $670 | $8 |
| Nifedipine Er | 17 | $633 | $37 |
| Torsemide | 42 | $557 | $13 |
| Isosorbide Mononitrate Er | 35 | $506 | $14 |
| Valsartan | 20 | $495 | $25 |
| Furosemide | 77 | $455 | $6 |
| Diltiazem | 21 | $379 | $18 |
| Hydrochlorothiazide | 117 | $371 | $3 |
| Benazepril | 14 | $364 | $26 |
| Nitroglycerin | 31 | $347 | $11 |
| Lisinopril | 60 | $265 | $4 |
| Famotidine | 14 | $261 | $19 |
| Clonidine | 22 | $222 | $10 |
| Simvastatin | 19 | $213 | $11 |
| Pravastatin | 12 | $162 | $14 |
| Omeprazole | 13 | $161 | $12 |
| Atenolol | 13 | $113 | $9 |
Year by year
| 2024 | 4,027 | 718 | 0% (0) | None | $1,334,468 |
| 2023 | 4,021 | 678 | 0% (0) | 26% | $1,288,084 |
| 2022 | 4,061 | 656 | 0% (0) | 25% | $1,090,138 |
| 2021 | 3,819 | 642 | None | 26% | $931,154 |
| 2020 | 2,879 | 558 | None | 29% | $666,304 |
| 2019 | 1,686 | 382 | 0% (0) | 30% | $371,809 |
| 2018 | 761 | 203 | 0% (0) | 22% | $108,124 |
| 2017 | 137 | 47 | 0% (0) | 23% | $33,079 |
| 2016 | 53 | 35 | None | None | $4,723 |
| 2015 | 22 | None | None | None | $3,680 |
| 2014 | 27 | 14 | 0% (0) | None | $4,947 |
| 2013 | 197 | 40 | 6% (11) | None | $9,494 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 43 drugs
| Eliquis | 438 | $550,646 | $1,257 |
| Entresto | 150 | $195,490 | $1,303 |
| Xarelto | 110 | $146,390 | $1,331 |
| Jardiance | 71 | $91,584 | $1,290 |
| Farxiga | 43 | $62,116 | $1,445 |
| Repatha Sureclick | 79 | $61,577 | $779 |
| Praluent | 32 | $26,608 | $832 |
| Brilinta | 13 | $13,967 | $1,074 |
| Ranolazine Er | 80 | $12,866 | $161 |
| Metoprolol | 362 | $9,848 | $27 |
| Atorvastatin | 398 | $7,240 | $18 |
| Rosuvastatin | 157 | $5,883 | $37 |
| Ezetimibe | 77 | $5,277 | $69 |
| Carvedilol | 189 | $3,211 | $17 |
| Flecainide Acetate | 38 | $2,854 | $75 |
| Amlodipine Besylate | 260 | $2,310 | $9 |
| Hydralazine | 94 | $2,140 | $23 |
| Clopidogrel | 127 | $2,072 | $16 |
| Losartan | 99 | $1,596 | $16 |
| Metoprolol | 130 | $1,583 | $12 |
| Diltiazem | 47 | $1,568 | $33 |
| Isosorbide Mononitrate Er | 48 | $1,332 | $28 |
| Olmesartan Medoxomil | 32 | $1,268 | $40 |
| Potassium Chloride | 23 | $1,249 | $54 |
| Isosorbide Dinitrate | 11 | $1,189 | $108 |
| Nitroglycerin | 42 | $1,094 | $26 |
| Diltiazem 24hr Er (Cd) | 24 | $1,003 | $42 |
| Spironolactone | 100 | $968 | $10 |
| Amiodarone | 26 | $937 | $36 |
| Torsemide | 48 | $899 | $19 |
| Diltiazem 24hr Er | 21 | $852 | $41 |
| Furosemide | 96 | $739 | $8 |
| Valsartan | 25 | $732 | $29 |
| Lisinopril | 60 | $601 | $10 |
| Chlorthalidone | 11 | $581 | $53 |
| Clonidine | 15 | $506 | $34 |
| Pravastatin | 28 | $416 | $15 |
| Benazepril | 23 | $356 | $15 |
| Omeprazole | 16 | $323 | $20 |
| Hydrochlorothiazide | 108 | $319 | $3 |
| Pantoprazole | 11 | $228 | $21 |
| Simvastatin | 12 | $172 | $14 |
| Atenolol | 13 | $149 | $11 |
2022: 46 drugs
| Eliquis | 418 | $449,831 | $1,076 |
| Entresto | 196 | $212,824 | $1,086 |
| Xarelto | 114 | $120,499 | $1,057 |
| Jardiance | 69 | $82,200 | $1,191 |
| Repatha Sureclick | 69 | $46,892 | $680 |
| Farxiga | 24 | $34,127 | $1,422 |
| Praluent | 21 | $14,361 | $684 |
| Ranolazine Er | 46 | $9,955 | $216 |
| Brilinta | 13 | $9,660 | $743 |
| Metoprolol | 339 | $9,301 | $27 |
| Atorvastatin | 459 | $7,842 | $17 |
| Rosuvastatin | 109 | $5,920 | $54 |
| Ezetimibe | 42 | $3,057 | $73 |
| Hydralazine | 151 | $2,743 | $18 |
| Carvedilol | 198 | $2,648 | $13 |
| Clopidogrel | 137 | $2,138 | $16 |
| Isosorbide Mononitrate Er | 73 | $1,921 | $26 |
| Amlodipine Besylate | 225 | $1,844 | $8 |
| Flecainide Acetate | 27 | $1,648 | $61 |
| Losartan | 117 | $1,641 | $14 |
| Diltiazem | 42 | $1,624 | $39 |
| Isosorbide Dinitrate | 21 | $1,598 | $76 |
| Metoprolol | 130 | $1,462 | $11 |
| Potassium Chloride | 32 | $1,136 | $35 |
| Nitroglycerin | 42 | $1,067 | $25 |
| Spironolactone | 112 | $996 | $9 |
| Pravastatin | 45 | $969 | $22 |
| Furosemide | 133 | $852 | $6 |
| Diltiazem 24hr Er (Cd) | 32 | $763 | $24 |
| Losartan-Hydrochlorothiazide | 25 | $750 | $30 |
| Valsartan | 20 | $694 | $35 |
| Famotidine | 29 | $613 | $21 |
| Diltiazem 24hr Er | 13 | $573 | $44 |
| Chlorthalidone | 17 | $561 | $33 |
| Torsemide | 35 | $489 | $14 |
| Lisinopril | 51 | $455 | $9 |
| Hydrochlorothiazide | 106 | $393 | $4 |
| Amiodarone | 12 | $340 | $28 |
| Sotalol | 11 | $330 | $30 |
| Digoxin | 11 | $305 | $28 |
| Levothyroxine | 11 | $267 | $24 |
| Benazepril | 19 | $264 | $14 |
| Pantoprazole | 20 | $221 | $11 |
| Simvastatin | 12 | $138 | $12 |
| Clonidine | 12 | $126 | $10 |
| Atenolol | 12 | $105 | $9 |
2021: 43 drugs
| Eliquis | 428 | $433,592 | $1,013 |
| Entresto | 200 | $200,083 | $1,000 |
| Xarelto | 104 | $104,510 | $1,005 |
| Repatha Sureclick | 119 | $60,475 | $508 |
| Brilinta | 20 | $13,121 | $656 |
| Praluent | 13 | $12,445 | $957 |
| Metoprolol | 304 | $8,829 | $29 |
| Rosuvastatin | 113 | $7,033 | $62 |
| Atorvastatin | 383 | $6,967 | $18 |
| Ranolazine Er | 22 | $3,903 | $177 |
| Isosorbide Mononitrate Er | 105 | $3,094 | $29 |
| Ezetimibe | 18 | $2,970 | $165 |
| Carvedilol | 209 | $2,807 | $13 |
| Diltiazem 24hr Er (Cd) | 42 | $2,630 | $63 |
| Hydralazine | 121 | $2,443 | $20 |
| Clopidogrel | 126 | $1,728 | $14 |
| Losartan | 118 | $1,657 | $14 |
| Potassium Chloride | 47 | $1,567 | $33 |
| Nitroglycerin | 41 | $1,433 | $35 |
| Furosemide | 196 | $1,379 | $7 |
| Flecainide Acetate | 26 | $1,356 | $52 |
| Pravastatin | 56 | $1,343 | $24 |
| Valsartan | 20 | $1,328 | $66 |
| Metoprolol | 136 | $1,219 | $9 |
| Amlodipine Besylate | 139 | $1,175 | $8 |
| Isosorbide Dinitrate | 20 | $1,098 | $55 |
| Diltiazem | 34 | $882 | $26 |
| Spironolactone | 86 | $781 | $9 |
| Lisinopril | 85 | $743 | $9 |
| Metolazone | 15 | $654 | $44 |
| Digoxin | 16 | $581 | $36 |
| Famotidine | 17 | $579 | $34 |
| Amiodarone | 16 | $380 | $24 |
| Hydrochlorothiazide | 87 | $380 | $4 |
| Omeprazole | 16 | $377 | $24 |
| Atenolol | 19 | $319 | $17 |
| Warfarin | 14 | $319 | $23 |
| Levothyroxine | 12 | $307 | $26 |
| Torsemide | 11 | $251 | $23 |
| Clonidine | 11 | $190 | $17 |
| Simvastatin | 25 | $153 | $6 |
| Benazepril | 14 | $148 | $11 |
| Pantoprazole | 13 | $83 | $6 |
2020: 37 drugs
| Eliquis | 328 | $296,166 | $903 |
| Entresto | 163 | $138,738 | $851 |
| Xarelto | 139 | $118,251 | $851 |
| Repatha Sureclick | 40 | $20,378 | $509 |
| Praluent | 17 | $9,485 | $558 |
| Metoprolol | 238 | $9,144 | $38 |
| Atorvastatin | 304 | $6,794 | $22 |
| Rosuvastatin | 83 | $5,921 | $71 |
| Ranolazine Er | 13 | $3,962 | $305 |
| Vascepa | 12 | $3,810 | $318 |
| Ezetimibe | 15 | $3,003 | $200 |
| Carvedilol | 182 | $2,407 | $13 |
| Isosorbide Mononitrate Er | 68 | $1,928 | $28 |
| Hydralazine | 57 | $1,307 | $23 |
| Clopidogrel | 84 | $1,284 | $15 |
| Flecainide Acetate | 18 | $1,277 | $71 |
| Diltiazem 24hr Er (Cd) | 23 | $1,157 | $50 |
| Losartan | 76 | $1,139 | $15 |
| Nifedipine Er | 12 | $1,111 | $93 |
| Potassium Chloride | 20 | $1,025 | $51 |
| Furosemide | 146 | $938 | $6 |
| Amlodipine Besylate | 120 | $925 | $8 |
| Diltiazem | 30 | $812 | $27 |
| Nitroglycerin | 23 | $735 | $32 |
| Metoprolol | 94 | $707 | $8 |
| Torsemide | 27 | $573 | $21 |
| Lisinopril | 62 | $565 | $9 |
| Spironolactone | 58 | $513 | $9 |
| Pravastatin | 25 | $512 | $20 |
| Warfarin | 21 | $472 | $22 |
| Amiodarone | 13 | $420 | $32 |
| Hydrochlorothiazide | 60 | $396 | $7 |
| Simvastatin | 33 | $266 | $8 |
| Omeprazole | 11 | $234 | $21 |
| Atenolol | 16 | $179 | $11 |
| Clonidine | 17 | $165 | $10 |
| Benazepril | 12 | $140 | $12 |
2019: 25 drugs
| Eliquis | 208 | $168,756 | $811 |
| Entresto | 104 | $83,786 | $806 |
| Xarelto | 50 | $44,546 | $891 |
| Praluent | 23 | $25,272 | $1,099 |
| Atorvastatin | 209 | $5,389 | $26 |
| Metoprolol | 110 | $4,300 | $39 |
| Carvedilol | 143 | $1,825 | $13 |
| Amiodarone | 14 | $1,701 | $121 |
| Nifedipine Er | 16 | $1,465 | $92 |
| Rosuvastatin | 20 | $1,141 | $57 |
| Amlodipine Besylate | 100 | $891 | $9 |
| Metoprolol | 90 | $787 | $9 |
| Potassium Chloride | 11 | $757 | $69 |
| Isosorbide Mononitrate Er | 32 | $724 | $23 |
| Clopidogrel | 40 | $698 | $17 |
| Furosemide | 103 | $590 | $6 |
| Hydralazine | 28 | $563 | $20 |
| Lisinopril | 60 | $524 | $9 |
| Nitroglycerin | 19 | $501 | $26 |
| Losartan | 32 | $423 | $13 |
| Warfarin | 11 | $191 | $17 |
| Spironolactone | 26 | $181 | $7 |
| Simvastatin | 13 | $160 | $12 |
| Hydrochlorothiazide | 33 | $153 | $5 |
| Pravastatin | 11 | $94 | $9 |
2018: 19 drugs
| Eliquis | 65 | $46,813 | $720 |
| Xarelto | 12 | $14,730 | $1,227 |
| Entresto | 16 | $12,874 | $805 |
| Atorvastatin | 89 | $2,147 | $24 |
| Metoprolol | 20 | $851 | $43 |
| Rosuvastatin | 16 | $793 | $50 |
| Carvedilol | 58 | $594 | $10 |
| Amlodipine Besylate | 44 | $564 | $13 |
| Metoprolol | 67 | $492 | $7 |
| Isosorbide Mononitrate Er | 22 | $471 | $21 |
| Clopidogrel | 28 | $447 | $16 |
| Amiodarone | 11 | $440 | $40 |
| Lisinopril | 38 | $391 | $10 |
| Furosemide | 54 | $322 | $6 |
| Diltiazem 24hr Er (Cd) | 11 | $310 | $28 |
| Hydralazine | 11 | $241 | $22 |
| Losartan | 17 | $187 | $11 |
| Hydrochlorothiazide | 29 | $158 | $5 |
| Nitroglycerin | 11 | $144 | $13 |
2017: 2 drugs
| Repatha | 12 | $20,674 | $1,723 |
| Atorvastatin | 23 | $881 | $38 |
2013: 2 drugs
| Atorvastatin | 11 | $377 | $34 |
| Furosemide | 11 | $72 | $7 |
Money from drug and device companies
$891 in 2025
| 2025 | 13 | 42 | None | $891 |
| 2024 | 11 | 29 | None | $560 |
| 2023 | 10 | 17 | None | $384 |
| 2022 | 4 | 7 | None | $145 |
| 2021 | 3 | 3 | None | $61 |
| 2020 | 8 | 13 | None | $249 |
| 2019 | 8 | 56 | None | $757 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Leqvio | $242 | 13 payments
|
| Alnylam Pharmaceuticals | Amvuttra | $164 | 7 payments
|
| Pfizer | Vyndaqel | $95 | 5 payments
|
| Inspire Medical Systems | Inspire | $83 | 2 payments
|
| BridgeBio Pharma | Attruby | $50 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $48 | 2 payments
|
See all 41 published payments
| Alnylam Pharmaceuticals | Meals · 2025-12-18 | Amvuttra | $11 |
| BridgeBio Pharma | Meals · 2025-12-18 | Attruby | $22 |
| Novartis Pharmaceuticals | Meals · 2025-12-17 | Leqvio | $22 |
| Scpharmaceuticals | Meals · 2025-12-10 | Furoscix | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-21 | Eliquis | $26 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-14 | Jardiance | $29 |
| Novartis Pharmaceuticals | Meals · 2025-10-27 | Leqvio | $25 |
| Kestra Medical Technology Services | Meals · 2025-10-23 | Assure Wcd | $17 |
| Alnylam Pharmaceuticals | Meals · 2025-10-15 | Amvuttra | $27 |
| Scpharmaceuticals | Meals · 2025-10-14 | Furoscix | $24 |
| Alnylam Pharmaceuticals | Meals · 2025-09-16 | Amvuttra | $23 |
| Novartis Pharmaceuticals | Meals · 2025-09-11 | Leqvio | $20 |
| Novartis Pharmaceuticals | Meals · 2025-09-11 | Leqvio | $0 |
| Novartis Pharmaceuticals | Meals · 2025-09-11 | Leqvio | $20 |
| Novartis Pharmaceuticals | Meals · 2025-09-11 | Leqvio | $0 |
| Inspire Medical Systems | Meals · 2025-09-10 | Inspire | $27 |
| Novartis Pharmaceuticals | Meals · 2025-08-20 | Leqvio | $26 |
| Novartis Pharmaceuticals | Meals · 2025-08-20 | Leqvio | $26 |
| Novartis Pharmaceuticals | Meals · 2025-08-11 | Leqvio | $20 |
| Alnylam Pharmaceuticals | Meals · 2025-08-06 | Amvuttra | $32 |
| Pfizer | Meals · 2025-07-30 | Vyndaqel | $20 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-07-28 | Lifevest | $16 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-23 | Jardiance | $19 |
| Kestra Medical Technology Services | Meals · 2025-07-10 | Assure Wcd | $14 |
| Inspire Medical Systems | Meals · 2025-07-09 | Inspire | $56 |
| Pfizer | Meals · 2025-07-02 | Vyndaqel | $21 |
| BridgeBio Pharma | Meals · 2025-07-01 | Attruby | $29 |
| Alnylam Pharmaceuticals | Meals · 2025-06-24 | Amvuttra | $24 |
| Pfizer | Meals · 2025-05-20 | Vyndaqel | $18 |
| Novartis Pharmaceuticals | Meals · 2025-05-13 | Leqvio | $21 |
| Cleerly | Meals · 2025-04-23 | Cleerly Ischemia | $23 |
| Novartis Pharmaceuticals | Meals · 2025-04-22 | Leqvio | $24 |
| Merck Sharp & Dohme | Meals · 2025-04-16 | Verquvo | $22 |
| Alnylam Pharmaceuticals | Meals · 2025-04-01 | Amvuttra | $26 |
| Novartis Pharmaceuticals | Meals · 2025-03-21 | Leqvio | $14 |
| Alnylam Pharmaceuticals | Meals · 2025-03-11 | Amvuttra | $22 |
| Pfizer | Meals · 2025-03-07 | Vyndaqel | $18 |
| AltaThera Pharmaceuticals | Meals · 2025-02-19 | Sotalol Hydrochloride | $30 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-02-04 | Lifevest | $13 |
| Novartis Pharmaceuticals | Meals · 2025-01-28 | Leqvio | $22 |
| Pfizer | Meals · 2025-01-23 | Vyndaqel | $18 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $560
| Pfizer | Vyndaqel | $137 | 7 payments
|
| Alnylam Pharmaceuticals | Amvuttra | $92 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $77 | 3 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $51 | 3 payments
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $46 | 3 payments
|
| Boston Scientific | Bodyguardian | $35 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $32 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $28 | 2 payments
|
| Abbott Laboratories | Mitraclip | $25 | 1 payment
|
| Amgen | Repatha | $19 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $18 | 1 payment
|
2023: $384
| Alnylam Pharmaceuticals | Amvuttra | $68 | 3 payments
|
| Boston Scientific | Eluvia | $67 | 3 payments
|
| Novartis Pharmaceuticals | Leqvio | $53 | 2 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $47 | 2 payments
|
| Pfizer | Vyndaqel | $40 | 2 payments
|
| Kestra Medical Technology Services | Assure Wcd | $36 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $22 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $18 | 1 payment
|
| Electromed | Smartvest | $17 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $16 | 1 payment
|
2022: $145
| Abbott Laboratories | Mitraclip | $95 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $22 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $14 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $14 | 1 payment
|
2021: $61
| Boston Scientific | Watchman | $24 | 1 payment
|
| Pfizer | Eliquis | $20 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $17 | 1 payment
|
2020: $249
| Akcea Therapeutics | Tegsedi | $66 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $43 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $39 | 2 payments
|
| Amgen | Repatha | $31 | 2 payments
|
| Abbott Laboratories | Mitra Clip System | $20 | 1 payment
|
| BSN Medical | None | $18 | 1 payment
|
| Boston Scientific | Watchman | $18 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $15 | 1 payment
|
2019: $757
| Novartis Pharmaceuticals | Entresto | $244 | 23 payments
|
| Pfizer | Eliquis | $163 | 14 payments
|
| Janssen Pharmaceuticals | Xarelto | $149 | 10 payments
|
| Amgen | Repatha | $86 | 4 payments
|
| Amarin Pharma | Vascepa | $35 | 2 payments
|
| Boston Scientific | General Therapies | $34 | 1 payment
|
| Akcea Therapeutics | Tegsedi | $29 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $17 | 1 payment
|
Professional record
- NPI
- 1205129731
- Licence
- CA A123190California A123190: Current · expires 2026-10-31
- Trained
- Stanford University School of Medicine, 2011 · 15 years ago
- Group
- Torrance Memorial Medical Center · Cor Healthcare Medical Associates · Torrance Health Association Inc · Southern California Hospitalist Network Medical Group Inc
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 2841 Lomita Blvd Ste 100, Torrance, CA, 90505
- NPI first listed
- 2011-05-17
- NPI last updated
- 2026-04-22
- NPI record certified
- 2026-04-22
This is when the NPI record was last certified, not a medical board exam.